PURA and AABB – Two Very Different Stocks Both Set to Run on Technicals And News

New York, NY – January 16, 2019

Puration, Inc. (USOTC: PURA), the maker of EVERx CBD Sports Water announced yesterday that the company had doubled its CBD beverage production schedule after its retail distributors sold out of their December orders and submitted new orders double the size of their previous orders.  Today, PURA is Rated VERY BULLISH based on technical analysis.  PURA is trading at a support base of $0.08 with a 52-week high of $0.25 and a standing analyst SPECULATIVE BUY recommendation and a TARGET PPS of $0.25.  PURA included in its press release yesterday a coming announcement of an upcoming event to celebrate the $1 million in sales milestone and to introduce all new EVERx CBD Sports Water packaging.  The news yesterday also included an upcoming new CBD Water formulation with 25 mg of CBD.  Based on technical analysis and upcoming news, PURA looks ready to run.

www.bullishinvestor.com

www.bullishinvestor.com

Asia Broadband Inc. (USOTC: AABB) was a Top 25 Gainer on the OTC yesterday adding over 100% to its PPS on record trading volume.  AABB’s extraordinary gross margin growth over the last year came to light and the market reacted accordingly.  Last year the company reported $277,000 in gross profit on $882,000 in revenue.  This year the company has already reported a 1000% increase in gross profit to $2.7 million.  Today, AABB is rated BULLISH.  The PPS is over $0.02 with a 52-week high of $0.10.  Yesterday’s move put AABB on the radar screen and the PPS is set to retrace to its $0.10 52-week high.

www.bullishinvestor.com

www.bullishinvestor.com

Asia Broadband Inc., through its wholly owned subsidiary Asia Metals Inc., is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets. The Company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Guerrero, Mexico, to our client sales networks in Asia. This vertical integration approach to sales transactions is the unique strength of Asia Broadband and differentiates the Company to its shareholders.

Hempamericana, Inc. (HMPQ) and Lithium Exploration Group, Inc. (LEXG) are also in the news and making radar screens and warrant a look. 

Disclaimer: 

NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

AABB PPS Ready To Explode On Report Of 1000% Gross Profit Growth To Over $3 Million

New York, NY – January 15, 2019 – The stock price per share of Asia Broadband Inc. (USOTC: AABB) is likely to explode when the company files its upcoming annual report.  Last year the company reported $277,000 in gross profit on $882,000 in revenue.  As of September 30, 2018, AABB has reported $2.7 million in gross profit just through the end of the third quarter.  2018 year-to-date (YTD) revenues through the third quarter have already exceeded total revenues for 2017 and the gross profit is up 1000%.  AABB has quietly snuck into the mining business with a unique twist connecting mineral resources in Mexico to buyers in China.  When the company files its annual report for 2018, there will be nothing quiet about this company any more.  Put this one on your radar.  AABB is trading at about $0.01 with a 52-week high of $0.10.  A PPS retrace to the $0.10 52-week high even before the annual report would not be a surprise.  With nearly $2 million in cash on the balance sheet now, a PPS much higher than the 52-week $0.10 high is well deserved.

Screen Shot 2019-01-15 at 8.35.18 AM.png

 About Asia Broadband Inc. - through its wholly owned subsidiary Asia Metals Inc., is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets. The Company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Guerrero, Mexico, to our client sales networks in Asia. This vertical integration approach to sales transactions is the unique strength of Asia Broadband and differentiates the Company to its shareholders.

Disclaimer: 

NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

USMJ - SHORT SQUEEZE ALERT With Bullish Rating and Reported As Most Shorted Stock By To REGSHO Data

New York, NY – January 9, 2019 – North American Cannabis Holdings, Inc. (USOTC:USMJ) current PPS at $0.0008 x $0.0009 (as of the writing of this report) presents an entry point opportunity for a potential near term double or better.  The PPS reached $0.0015 with a substantial trading volume over $0.001.  At the same time, the short volume collected in FINRA’s REGSHO data and reported by OTCShortReport puts USMJ on the most shorted OTC stocks list.  USMJ has also consistently been rated BULLISH by Stock Technical Analysis (Stockta.com).  Even now, with the PPS price dip, the Long-Term Rating remains BULLISH.  It appears an overly optimistic bear has shorted and may have overestimated the opportunity to pick up low-priced stock. A short cover, combined with USMJ’s ongoing business progress to include a soon-to-be launched cannabis ecommerce site and a shareholder dividend distribution, and the PPS can reasonably rocket back to the recent $0.0015 level and potentially go even higher.  A near term $0.002 does not seem unreasonable and a longer term $0.005 within the first quarter could be possible.

Screen Shot 2019-01-09 at 9.57.50 AM.png

 

Disclaimer: 

NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

Microcap Cannabis Stocks Ready To Rally On APPL China Trade War News – KALY PURA USMJ HEMP

Tim Cook, Chief Executive Officer of Apple, speaks as President Donald Trump listens during an American Technology Council roundtable in the State Dinning Room of the White House, Monday, June 19, 2017, in Washington. (AP Photo/Alex Brandon)

Tim Cook, Chief Executive Officer of Apple, speaks as President Donald Trump listens during an American Technology Council roundtable in the State Dinning Room of the White House, Monday, June 19, 2017, in Washington. (AP Photo/Alex Brandon)

New York, NY – Jan 3, 2019 – Apple (APPL) reported today that holiday earnings are off and CEO Tim Cook points to President Trumps trade war with China as the primary factor.  Rising interest rates, a Government shutdown and a simmering trade war are all together injecting a shadow of fear uncertainty and doubt (FUD) into the stock market.  Often, when the major exchanges slow, decline or in general experience the ramifications of FUD, the microcaps surge.  Maybe the microcaps get more attention while big board traders look for opportunity elsewhere while waiting out whatever storm has set upon their usual domain.  We can be certain of cause and effect, but a correlation certainly exists.  And this time around, not only might the microcaps garner the attention of big board traders looking for a safe haven, cannabis stocks are getting the additional boost of the 2018 Farm Act legalizing hemp farming in the United States.  Keep an eye on microcap cannabis stocks, not exchange listed cannabis stocks, but OTC cannabis stocks positioned to benefit from the legalization of hemp farming.  Here are a few showing signs of an impending rally:

Kali, Inc. (USOTC: KALY) has recently acquired a patented cannabis extraction process changing its entire business. The company has announced $400,000 in contracts since making the acquisition.  The company has also released pre-clinical research on cannabis extracts from its patented process conducted in partnership with universities.  KALY is trading in the $0.02 to $0.03 range and a PPS of $0.10 would not be a surprise.  KALY is rated OVERALL BULLISH.

Puration, Inc. (USOTC: PURA)  has licensed the KALY patented extraction process for the production of what is now the leading CBD infused sports beverage in the sports nutrition market – EVERx CBD Sports Water.  The company has $1 million in sales in 2018. PURA has been recently rated a BUY. The PPS has climbed recently to $0.09 from a support base at $0.08 after pulling back from a 52-week high of $0.25 and now showing signs of rebounding to its $0.25 52-week high. 

North American Cannabis Holdings, Inc.(USOTC: USMJ) has recently broken out on high volume.  The PPS has made a dramatic move above $0.001.  The 52-week high is $0.0025.  The company has recently announced a $10 million revenue goal for 2019 based on its new ecommerce business.  The company has also announced a pending dividend.  With a positive cannabis market and progress toward the $10 million revenue goal, the USMJ PPS has the potential to break above $0.01.

Hemp, Inc. (USOTC: HEMP), by its name alone, has garnered a great deal of attention in the wake of the 2018 Farm Act legalizing hemp farming.  HEMP trading volumes are up and the PPS is basing around $0.03 and preparing for likely run.

Disclaimer: 

NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

USMJ PURA KALY and MJNA Rated BULLISH In Anticipation of 2019 HEMP BOOM

New York, NY – December 28, 2018 – North American Cannabis Holdings, Inc. (USOTC:USMJ), Puration, Inc. (USOTC: PURA), Kali, Inc. (USOTC: KALY) and Medical Marijuana, Inc. (USOTC: MJNA) have all been rated BULLISH by Stock Technical Analysis (Stockta.com).  The cannabis sector, particularly companies with a strong hemp related presence, have seen increased investment interest since President Trump signed the Farm Act into law legalizing hemp farming. 

PURA, In fact,  has been rated VERY BULLISH having established a substantial support base at $0.08 after pulling back from a 52-week high of $0.25 and now showing signs of rebounding to its $0.25 52-week high. 

Screen Shot 2018-12-27 at 9.15.57 AM.png

 USMJ has recently broken out on high volume.  The PPS has made a dramatic move above $0.001.  The 52-week high is $0.0025.  The company has recently announced a $10 million revenue goal for 2019 based on its new ecommerce business.  The company has also announced a pending dividend.  With a positive cannabis market and progress toward the $10 million revenue goal, the USMJ PPS has the potential to break above $0.01.

Screen Shot 2018-12-27 at 9.17.22 AM.png

KALY has recently acquired a patented cannabis extraction process changing its entire business. The company has announced $400,000 in contracts since making the acquisition.  The company has also released pre-clinical research on cannabis extracts from its patented process conducted in partnership with universities.  KALY is trading in the $0.02 to $0.03 range and a PPS of $0.10 would not be a surprise.

Screen Shot 2018-12-27 at 9.18.31 AM.png

MJNA is also rated VERY BULLISH with a PPS currently trading at $0.08 with a 52 week high of $0.18.  With the positive cannabis sector environment resulting from the recent passage of the Farm Act combined with MJNA’s steady business plan, MJNA seems set for a rebound to it $0.18 52-week high.

Screen Shot 2018-12-27 at 9.20.02 AM.png

Disclaimer: 

NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

ALYI ALERT – BUY Recommendation Following Boost To Hemp Energy Strategy With Legalization of Hemp Farming

New York, NY – December 26, 2018 – Alternet Systems, Inc. (USOTC: ALYI) is rated a BUY today by AmericanBulls.com.  ALYI’s hemp energy strategy is getting a major boost from the recent signing of the Farm Act by President Trump legalizing hemp farming.  In October of this year, Alternet initiated a project to explore and develop hemp-based technologies for energy storage.  The company engaged Clarkson University Professor David Mitlin to lead the initiative.  Professor Mitlin is a leading expert in electrochemistry and a pioneer in the use of hemp as a clean, green, renewable energy in the form of a supercapacitor.  Mitlin has successfully used hemp bast – the fiber left over from processing hemp – to construct carbon nanosheets that compete with, and in some respects, outperform the supercapacitor performance derived from more typical graphene nanosheets. 

Screen Shot 2018-12-26 at 8.35.59 AM.png

AmericanBulls.com on ALYI

“Our system’s recommendation today is to BUY. The BULLISH HOMING PIGEON pattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0080, and our valid average buying price stands now at 0.0081.

Let’s jump on our white horses and go for a bullish ride. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. The market is telling you about a new profit. Do not miss this bullish opportunity.” 

Goldman Small Cap Research For ALYI - Speculative-Buy and $0.09 Target PPS 

Goldman Small Cap Research recently issued an updated research report on ALYI. The report includes a 'speculative-buy' rating with a target price-per-share of $0.09. The report provides an in-depth overview and analysis of Alternet's new strategy, new orders, and upcoming milestones. To view the report, along with disclosures and disclaimers, visit https://www.alternetsystemsinc.com/research-rpt/ or http://www.GoldmanResearch.com.  Management indicates that the company will engage Goldman to issue another update in the event the company reaches its first million in revenue by year end, 2018.

Other cannabis stocks making news today include Rocky Mountain High Brands (RMHB) with its legal battle, Dewmar International BMC (DEWM) with its new cannabis website and Medical Marijuana (MJNA) with its entry into Mexico.

Disclaimer: 

NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

KALY and GNBT Could Give GWPH Run For Money In 2019 - See Motley Fool Prediction

New York, NY - Dec 24, 2019 - Kali, Inc. (dba/Kali-Extracts) (USOTC: KALY) and Generex Biotechnology Corp (OTCQB: GNBT) through a deal announced between GNBT and US Cannabis Health, a Joint Venture partnership between KALY and Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals (USOTC: NOUV) could potentially soon introduce a cannabis drug that not only rivals GW Pharmaceuticals’ (NASDAQ: GWPH) Epidiolex, KALY and GNBT’s cannabis drug development could reveal that GWPH’s Epidiolex infringes on GNBT patents.

"I believe the underlying value of Kali-Extracts cannabis biotechnology properties are as of yet unrecognized by the market," said Frederick Ferri, CEO of Kali-Extracts. "Doctors involved in research with our extracts have given me feedback that our extracts are superior to those of GW Pharmaceuticals [GW Pharmaceuticals, plc (GWPH)].  As just one example of what our cannabis biotechnology can lead to, I believe our developing COPD therapies in combination with the potential for us to harness the patented RapidMist buccal cavity drug administration technology of Generex [Generex Biotechnology, Corp. (GNBT)] through our US Cannabis Health partnership, would put Kali-Extracts in front of any cannabis biotechnology company on the market.  For that matter, I think Generex applying its patented RapidMist buccal cavity administration technology would bode well for Generex as well.  I also happen to think that the combination of our COPD technology with the RapidMist technology of Generex would illustrate that GW Pharmaceuticals buccal drug administration is likely an infringement on Generex's RapidMist patent. In summary, the market has a lot yet to learn about Kali-extracts cannabis biotechnology.  I hope the COPD example herein begins to give a glimpse of that yet to be realized value.  Finally, I think the developing partnership between KALY and its other US Cannabis Health partners with Generex can put KALY, its other US Cannabis Health partners and Generex on top of their respective markets." (source - yahoo.com)

The-Motley-Fool-Logo.png

KALY and GNBT could impact Motley Fool’s 2019 prediction for GWPH. See Motley Fool’s prediction #4 of 7 for cannabis stocks in 2019:

4. First U.S. plant-based cannabinoid drug is a big hit, Big Pharma execs injure themselves after slapping foreheads in regret

Despite some nattering negativism by skeptics, GW Pharmaceuticals' (NASDAQ: GWPH) Epidiolex, the first plant-based cannabinoid drug approved in the U.S., becomes a smashing commercial success. Even pessimistic analysts project that Epidiolex likely will become a blockbuster within a few years.

As Epidiolex sales steadily increase, several renowned Big Pharma executives are forced to receive medical care for injuries received from slapping themselves on the foreheads in regret. These slaps stem from the executives reading the histories of their companies marketing cannabis-based drugs in the early 20th century. (Source: Motley Fool)

Keep an eye on KALY and GNBT. Both are showing characteristics of entry level prices you might regret missing.

Learn more about Kali, Inc. at www.kali-extracts.com.

Learn more about Generex at www.generex.com.

Disclaimer: 

NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. 

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

 



PURA BUY RECOMMENDATION FOLLOWING FARM ACT – $0.25 PPS REBOUND ON HORIZON

New York, NY – December 21, 2018 - Puration, Inc. (USOTC: PURA) has a BUY recommendation from AmericanBulls.com following President Trump signing the Farm Bill into law and legalizing hemp farming.  The company also announced yesterday exceeding its $1 million sales goal for 2018 and setting a $5 million sales goal for 2019.  The company is thriving and growing and showing now reason not to be trading at the $0.25 PPS high reached a few weeks ago and supported by a sustained Goldman Small Cap Research PPS Target Recommendation.  Bulls make money on increasing share prices and bears make money selling short and buying shares to fill short sales executed at a higher price.  REGSHO data (see below) shows that PURA has been consistently sold short for weeks now.  Yesterday and this morning the PURA PPS rallied only to have cold water poured on the rally by Citadel Securities (CDEL) boxing the bid and offer and scuttling the rally.  CDEL has dominated the box for weeks while the PPS has gone sideways with likely short sellers picking up the shares of legitimate and frustrated shareholders.  Farm Act news and positive sales results from PURA sparked the rally that threatened short position holders. The rally and subsequent effort to scuttle the rally also exposed the short position.  The short position can’t likely hold on much longer.  PURA looks to have even more good news coming to include a pending dividend.  The rally showed the shorts control is weakening.  A $0.25 PPS rebound looks to be on the horizon.

AmericanBulls Buy Recommendation:

“Our system’s recommendation today is to BUY. The BULLISH HARAMI pattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0872, and our valid average buying price stands now at 0.0880.

Let’s jump on our white horses and go for a bullish ride. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. The market is telling you about a new profit. Do not miss this bullish opportunity”

Screen Shot 2018-12-21 at 10.17.36 AM.png

PURA REGSHO Short Data

Screen Shot 2018-12-21 at 10.18.15 AM.png

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

KALY – New Cannabis Biotech On Scene With Near Term PPS Potential To $0.10

New York, NY – December 21, 2018 Kali, Inc. (USOTC: KALY) executed a reverse merger last month acquiring a patented cannabis extraction asset.  As the company cleans up its filings and updates its website, it is becoming clear that there is a lot here under the hood.  Not only does the company have a patented cannabis extraction process, it has a substantial amount of research behind cannabis extracts derived from the patented extraction process.  The company just release news this week (see below) on research conducted with Beach Tree Labs and Brown University for a cannabis extract therapy for respiratory diseases.  This research was intended as an example of more research yet to be disclosed.  The news indicated further research study information would be forthcoming.  The company has already attracted the attention of Generex Biotechnology (OTCQB: GNBT) that has FDA trials underway with the likes of Merck (NYSE: MRK). If KALY’s partnership with GNBT advances to trial stage or if GNBT signs a second pharmaceutical company, KALY can arguably justify a $100 million valuation and $0.10 PPS.  Even now, with preclinical research results for a respiratory condition with an $11 billion therapy market, where a 1 percent penetration of that market would be over $1 billion dollars, KALY can justify a higher valuation today than the current PPS.  Comparing KALY to other OTC quoted biotechs; taking into account the OTC transparency concerns, but also considering the $400,000 in revenue contracts (see below) KALY has recently announced, a $0.05 PPS today does not seem out of the question.

KALY Highlights:

Kali-Extracts, Inc. Releases Preclinical Research Study Results on Therapy for Respiratory Disease Driving $11 Billion Treatment Market

Kali-Extracts Inc. Announces $300,000 Contract to Produce Hemp-Derived CBD Extract for Puration Inc.

KALY - Kali-Extracts Announces $100,000 Order of its Hemp4mula CBD Infused Chewing Gum Available Soon on USMJ E-commerce Site

Kali-Extracts and Nouveau Announce 100 Acer Hemp Farm and CBD Extraction Facility Made Possible By New Farm Bill

KALY Short Squeeze

The KALY PPS has gone in the last month from $0.003 to over $0.03.  As with any such meteoric, the trading has attracted its fair share of short sellers.  In fact, KALY has been reported all week as one of the top 11 most shorted stocks on the OTC.  Yesterday, the PPS dropped below $0.02 as a result of a short raid, but not on a lot of volume.  The PPS popped at the open today almost going back to $0.03.  There is definitely a short squeeze here and if all that KALY has under the hood gets a little more market attention, the short cover will contribute to pushing the KALY PPS to the $0.05 it arguably deserves today and maybe even higher.

Screen Shot 2018-12-21 at 9.22.49 AM.png


US Cannabis Health

KALY is partners with Puration, Inc. (USOTC: PURA) and Nouveau Life Pharmaceuticals, Inc. (USOTC: NOUV) in a joint venture named US Cannabis Health for the purpose of together developing partnerships with pharmaceutical companies to develop cannabis pharmaceuticals.  US Cannabis Health recently announced its first agreement with Generex Biotechnology, Corp. (OTCQB: GNBT).

Learn more about Kali, Inc. at www.kali-extracts.com.


Disclaiemer: 

NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

PURA Rated BULLISH Following News with KALY on 1st Shipment of $1 Million Order

Screen Shot 2018-12-14 at 11.04.10 AM.png

New York, NY – November 14, 2018 - Puration, Inc. (PURA) is rated BULLISH today by BullishInvestor.com after the company yesterday announced with Kali, Inc. (KALY) the first shipment of a private label CBD infused water with a custom extract from KALY.

Kali-Extracts and Puration Announce First Shipment Of Hemp-Derived CBD Infused Private Label Water For Pharmaceutical Client

Screen Shot 2018-12-13 at 10.36.21 PM.png

From the PURA and KALY News

“… announced shipping the first private labeled, hemp-derived CBD infused, high alkaline water to Generex Biotechnology Corporation (OTCQB: GNBT) in conjunction with a previously announced agreement to produce $1 million of CBD infused water for Generex.  PURA is producing the CBD infused water for Generex and PURA has in turn engaged KALY in a $300,000 contract to produce the CBD extract specific to the requirements of Generex. 

KALY and HEMP Positioned To Benefit From $867 Billion Farm Bill

After Congress passed the $867 Billion Farm Bill legalizing hemp farming, KALY and Hemp, Inc. (HEMP) were both found on the OTCMarkets top 10 most active traders by share volume list. KALY is on the list again today, though HEMP has slipped down slightly while still in the top 20.  Another company benefiting from the Farm Bill that hs moved up today’s top 10 list is USMJ.  The large trading volumes at these levels is a reasonable indication that a base is building for bigger gains.

Screen Shot 2018-12-14 at 11.00.57 AM.png

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

KALY Rated a BUY with PPS up 60% to $0.005 Heading To $0.01 Potential Breakout

American Bulls Logo and KALY.jpg

New York, NY – December 12, 2018 Kali, Inc. (USOTC: KALY) was recommended as a BUY today by AmericanBulls.com.  The KALY PPS has advanced over 60% so far this week on high trading volume.  KALY has been one of the top 50 most actively traded stocks on OTCMarkets for two straight days reaching over $100,000 in trading volume on Monday and over $200,000 in trading volume on Tuesday. On November 1st, the KALY PPS tested a $0.01 breakthrough on news of a LOI to acquire a patented cannabis extraction process.  KALY has since closed the acquisition and announced $300,000 contract to extract hemp-derived CBD, and plans to introduce its own hemp-derived CBD gum before the end of the year.  The company has indicated its intentions to have all public information current on the OTCMarkets soon.  KALY’s acquisition and sales progress is positioned for a boost from developments in the overall hemp-derived CBD market with the pending legalization of hemp anticipated in the 2018 Farm Act now approved by the Senate and expected to be signed into law by President Trump before the end of the month.  KALY momentum is building and the PPS is currently out performing other cannabis stock leaders like Hemp, Inc. (HEMP), Pot Networks (POTN) and Cannabis Science (CBIS).  KALY momentum continues to build and now with the patented cannabis extraction asset on its balance sheet and generating revenue, the KALY PPS looks on track to soon be trading over $0.01

Screen Shot 2018-12-12 at 7.21.01 AM.png

AmericanBulls.com

“Our system’s recommendation today is to BUY. The BULLISH ONE WHITE SOLDIERpattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0039, and our valid average buying price stands now at 0.0040.”

“Let’s jump on our white horses and go for a bullish ride. The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. The market is telling you about a new profit. Do not miss this bullish opportunity.”  

Learn more at www.kali-extracts.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

KALY Trading At $0.004 On High Volume Above 50 Day MA With Potential To Break $0.01

KALY LOGO.jpg

New York, NY – December 11, 2018 Kali, Inc. (USOTC: KALY) today is one of the top 50 most actively traded stocks on OTCMarkets along with Hemp, Inc. (HEMP), North American Cannabis Holdings, Inc. (USMJ) and Hemp America, Inc. (HMPQ).  The KALY PPS moved up 30% yesterday on over $100,000 of trading volume and the PPS is up again today.  KALY continues to be rated VERY BULLISH by Stockta.com.  KALY is trading above its 200, 100, and 50 Day Moving Averages. Just over 30 days ago, in the midst of the Canadian recreational marijuana legalization market surge, KALY hit a high of $0.009 pushing the penny boundary.  Since then, KALY has acquired a patented cannabis extraction process and the associated pharmaceutical research that came with the patent, additionally  announcing a $300,000 contract to extract hemp-derived CBD, and plans to introduce its own hemp-derived CBD gum before the end of the year.  The company has recently begun updating the new post patent acquisition information on OTCMarkets and has indicated its intentions to have all public information on the OTCMarkets updated soon.  With the newly acquired patented cannabis extraction asset, a signed $300,000 contract, the production of its own CBD infused product underway, and updated public disclosures, all combined with the pending legalization of hemp farming included in the 2018 Farm Act signed by Senator Mitch McConnell yesterday (using a hemp pen), KALY looks poised to break through the $0.01 before the end of the year.

KALY Chart DEC 11.png

90 days ago, KALY’s PPS was lingering on low volume between $0.0003 by $0.0004.  In mid-October, KALY trading came to life when the company announced an LOI to acquire the patented cannabis extraction process.  All total, in the last 90 days, the trading volume has turned over the issued and outstanding almost five times at a weighted average PPS of just under $0.003 reaching a high of $0.009 on November 1st.  Since the market cooling off following the Canadian recreational marijuana legalization market surge, KALY trading has hovered around the $0.003 90 day weighted average.  Yesterday, after KALY announced its $300,000 hemp-derived CBD extraction contract, the PPS started to move north. As the cannabis market heats up in conjunction with the U.S. anticipated legalization of hemp farming as drafted into the pending 2018 Farm Act, KALY is staged, both business development wise and stock technical wise, to realize a substantial PPS climb.

Learn more at www.kali-extracts.com.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

KALY Rated VERY BULLISH with PPS up 30% on High Volume After $300K CBD Extract Contract Announcement

New York, NY – December 10, 2018 Kali, Inc. (USOTC: KALY) is rated VERY BULLISH today by Stockta.com after the company announced a $300,000 contract to extract hemp-derived CBD.  The PPS is up over 30% and KALY trading volume is in the top 50 most actively traded stocks on OTCMarkets.

Screen Shot 2018-12-10 at 12.54.48 PM.png

“With the legalization of hemp farming on the near horizon as drafted into the pending 2018 Farm Act, the flood gates are about to open for Kali-Extracts,” Said Frederick Ferri, the founder of NCM Biotech, and the incoming CEO of Kali-Extracts. “I am already receiving daily inquiries to formulate custom hemp-derived CBD extractions.  The pending legalization of hemp farming, combined with the recent DEA removal of CBD from schedule 1, is igniting the commercialization of hemp-derived CBD concentrates for a multitude of applications from pharmaceutical to sports nutrition to over the counter pain management to general health and wellness.”

Learn more about NCM Biotech at www.kali-extracts.com.

Other cannabis companies in the top 50 most actively traded on the OTCMarkets today include North American Cannabis Holdings, Inc. (USMJ), HEMP, In.c (HEMP), and Enviro-Serv (EVSV).

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

 

Source: www.nextbigticker.com

 

 

 

 

GNBT ALERT – PPS Could Break 52 Week $25 High As Apex Clearing Firm Buys Back Phantom GNBT Stock Mistakenly Issued In Tech Glitch

New York, NY – November 23, 2018 – Generex Biotechnology Corp (OTCQB: GNBT) issued an announcement on Wednesday this week to warn shareholders that Apex Clearing Firm had mistakenly issued phantom GNBT stock.  Sales of the phantom stock were the likely cause of a GNBT PPS decline on Wednesday.  Any sale of the phantom stock is effectively a short sale and Apex will be required to purchase shares to cover such short sales.  All short sales will have to be covered with the purchase of stock within three trading days.  The APEX buy back could trigger a GNBT run back to the recent 52 week high of $25.  GNBT has been very active of late with major acquisitions and the initiation of clinical trials.  The combination of positive GNBT news and the APEX buy back could give investors a substantial ROI.

Generex is currently a quiet giant of a pharmaceutical company that most people probably are not yet aware even exists.  Do a little research and you will find Generex is loaded with proprietary, intellectual property protected pharmaceutical technology. 

Learn more about Generex at http://www.generex.com/

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

PURA ALERT – BUY Recommendation Issued Following Research Coverage Update With $0.25 PPS Target Confirmation

New York, NY – November 20, 2018 - Puration, Inc. (PURA) received a BUY recommendation from AmericBulls.com after the Goldman Small Cap Research yesterday released an update to its ongoing research coverage of PURA that confirmed a Speculative BUY and $0.25 PPS Target PPS.

Screen Shot 2018-11-21 at 7.21.40 AM.png

Americanbulls.com:

“Our system’s recommendation today is to BUY. The BULLISH STOP LOSS pattern finally received a confirmation because the prices crossed above the Stop Loss level which was at 0.1089, and our valid average buying price stands now at 0.1091.

A rally after a bear setup can occasionally turn into an explosive long trade. We may be on the verge of catching one of them. There is now a strong positive sentiment in the market despite the absence of a bullish pattern. The bullish stop loss is finally confirmed, and a BUY signal is generated. The Market wants to reward the bulls. It may be the right time to be part of this boost and bullish market sentiment by joining the growing bullish crowd.”

Goldman Small Cap Research:

“PURA announced very strong 3Q18 results and the best is yet to come. As a result, we believe that current prices represent a terrific entry point for opportunistic investors. Moreover, we expect PURA could return to its 52-week high of $0.25 early next year, on the heels of products with new, upgraded packaging which will begin reaching stores next week. PURA’s new package form is priced at a convenient $20 per 4-pack. Management believes that this new form will take sales to the next level.

We believe our forecasts are conservative. For 2019, we estimate sales will reach $3M, with operating profit of $800,000. It should be noted that these figures exclude any contributions from new products which are likely to be introduced in the coming weeks. Separately, an under the radar near-term catalyst is the pending dividend related to the transaction with Nouveau Life Pharmaceuticals, (OTC - NOUV). NOUV formally declared a 1:5 stock dividend whereby NOUV common will be issued to PURA shareholders at a ratio of one NOUV common share for every five shares of PURA held on the yet to be determined date of record.  Although this event is not factored into the current stock price, we believe these shares could rise ahead of the record date announcement.“

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

KALY – Green Lighted and Recommended as Screaming “BUY” Following Patented Cannabis Extraction Acquisition

New York, NY – November 16, 2018 Kali, Inc. (USOTC: KALY) is recommended as a “BUY” today by AmericBulls.com following yesterday’s announcement that KALY had finalized the acquisition of NCM Biotech, the developer and owner of a patented cannabis extraction process - U.S. Patent No. 9,199,960 entitled “METHOD AND APPARATUS FOR PROCESSING HERBACEOUS PLANT MATERIALS INCLUDING THE CANNABIS PLANT.”  The KALY news reported the company plans to leverage the patent to enter the cannabis pharmaceuticals and concentrates market.  The news yesterday further reported that the cannabis pharmaceuticals market is forecasted to reach $50 billion in sales by 2029, and that the cannabis concentrates for wellness, edibles and recreational markets is forecasted to reach $8.5 billion in annual sales by 2022.

AmericanBulls.com:

“Our system’s recommendation today is to BUY. The BULLISH HARAMI pattern finally received a confirmation because the prices crossed above the confirmation level which was at 0.0038, and our valid average buying price stands now at 0.0039 …

The green light is on and this security is now screaming BUY. It is action time! The bullish pattern that was previously identified is finally confirmed and a BUY signal is generated. Most probably, it is the right time to participate in bullish fervor. Do not miss this bullish opportunity.” 

Screen Shot 2018-11-16 at 7.38.38 AM.png

KALY’s news yesterday included more information on the company’s plans to expand with a differentiated service in the cannabis pharmaceuticals and concentrates sector.  “Kali, with its recent acquisition of NCM Biotech, has separately announced entering into a joint venture (JV) company called US Cannabis Health with Puration [PURA] and Nouveau life Pharmaceuticals (USOTC: NOUV).”

Notably, the news yesterday emphasized that KALY had no plans for a reverse split in conjunction with the patented cannabis extraction acquisition.

In reference to what all comes with the acquisition, KALY’s news yesterday included the following:

“NCM Biotech’s current research and ongoing pharmaceutical developments come with the acquisition.  Commenting on the research NCM Biotech has undertaken with notable medical institutions in the North East, Frederick Ferri, CEO and Founder of NCM Biotech said, “Some feedback has specifically indicated that a number of our candidate pharmaceutical products under development have a greater efficacy potential than GW Pharmaceutical [GWPH] products and candidate products. “ “

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

 

EVSV - Enviro-Serv Rated VERY BULLISH on Cannabis News and Florida Election Prospects

New York, NY – October 30, 2018 – Enviro-Serv Inc. (USOTC: EVSV) continues with a VERY BULLISH rating based on candle stick analysis after the company announced plans to enter the cannabis sector as as service provider to hemp farmers. The company has hinted at a pending strategic announcement with a recognized cannabis sector company coming soon. Being headquartered in Florida, the midterm election results today could have a positive impact on the company’s cannabis sector plans with more pro legal marijuana elected officials coming into office.

Screen Shot 2018-11-06 at 9.03.27 AM.png

“The stock price direction for the day for EVSV is UP. The stock is experiencing a strong uptrend as of late … Based on BullishInvestor.com’s proprietary algorithms, EVSV is currently signaling VERY BULLISH.

… Overall the technical indicators are signaling a bullish reading for EVSV. As such, it may be a wise decision to consider EVSV at these price levels …

Since the stock is currently rated VERY BULLISH, investors are encouraged to take a closer look at this stock from a technical analysis perspective.”

NextBigTicker.com has also recently featured West Coast Venture Group, Corp (WCVC), Puration, Inc. (PURA) and Optec International (OPTI).

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor 

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com

LDSR’s Data443 Headlines with Microsoft and Facebook In BIGToken Feature On $124 Billion Data Privacy Market

New York, NY – November 6, 2018 - LandStar, Inc. (OTCPK: LDSR), the parent company of Data443™ Risk Mitigation, Inc. (“Data443”), a leading data security and privacy company, is featured in a release from BIGToken, a consumer Blockchain platform.  The BIGToken feature was released yesterday addressing the burgeoning Data Privacy market.  The feature includes quotes from Facebook (NASDAQ: FB) CEO Mark Zuckerberg, Microsoft (NASDAQ: MSFT) CEO Satya Nadella, Jason Remillard, CEO and founder of LDSR’s Data443.  The article is included below, in addition to a link to the original article.  The article has been republished here to emphasize the as of yet undiscovered LDSR opportunity.  LDSR closed yesterday at $0.005 at the same time it was featured in an article with Microsoft and Facebook.  Recent analyst coverage recommended LDSR at a Speculative BUY with a $0.027 Target PPSWith LDSR being featured by the Data Privacy industry side by side with Micrsoft and Facebook, it appears that LDSR is undervalued and that even the over 400% ROI that would be realized at the $0.027 Target PPS, might not adequately represent LDSR’s underlying value.

Big Token.png

BIGtoken Team -The blockchain platform for consumers to own, verify, and sell their data.

Nov 5

Microsoft CEO Says Data Privacy is a Human Right: The Week in Data Privacy and Transparency

In this week’s data privacy news, the CEO of Microsoft urges tech companies to focus on data privacy, Mark Zuckerberg announces Facebook’s data privacy timeline, Data443 releases an innovative data security product, and more.

Laptop Image.png

Microsoft CEO Satya Nadella speaks out about data privacy

In a keynote address this past Thursday, Nadella voiced his support for privacy as a “human right.” He focused on three major elements: privacy, cybersecurity and AI ethics. He cited EU’s General Data Protection Regulation (GDPR) as a model form of legislation. This nod follows a similar sentiment from Apple CEO Tim Cook, who championed the legislation at a talk this month as well. Nadella urged companies to see common citizens and small businesses as the most vulnerable to cyber threats, and tasked them with using their power to protect them.

“We need to use our collective prowess and power to protect these most vulnerable of populations, and it requires not just our industry but also nation states to be part of that,” he said. His final note touched on the importance of regulating AI as the impressive technology continues to develop. The need for ethical standards around artificial intelligence is becoming dire, and it’s the responsibility of massive tech companies like Microsoft and Apple to reckon with the consequences of this innovation.

Mark Zuckerberg sees major privacy updates coming in 2019

In a third-quarter earnings call with analysts, Facebook CEO Mark Zuckerberg reportedly claimed that some much-needed privacy updates are coming in 2019. “A few years ago, Facebook was very behind where it needed to be,” Zuckerberg said. “We started a three-year roadmap through the end of 2019 to get our systems to the level where we think we should be at — systems that can flag information that we think might be problematic to a much larger security and review team.” He went on: “But we are up against sophisticated adversaries and threats will continue to evolve.” He reassured them by saying that the company is getting better and better at detecting threats and eliminating them.

More specifically, Zuckerberg claimed that the platform has flagged several groups from Russia and Iran who have been using social media to sway elections and encourage political and social divisions in the U.S., the UK and elsewhere. But he cited the massive growth of Facebook users as the key issue moving forward. Facebook had 2.27 billion monthly average users in September. It’s estimated that more than 2.6 billion people now use Facebook, WhatsApp, Instagram, or Messenger each month.

Zucherburg.png

New security product from Data443 is a major step forward

Data443 released version 1.43 of ClassiDocs last week, which is a huge advancement for data privacy tech and GDPR compliance. The system uses a Data Repository Owner Identification technology to securely manage data, and help businesses comply with GDPR in a number of ways. “Data privacy and GDPR response continue to drive IT spending worldwide,” said Jason Remillard, founder of Data443. “And these factors are just as important if not more so for the vast number of companies that use cloud services to manage and conduct their business. Our mission has always been to deliver industry-leading cybersecurity products that empower organizations to solve real-life data challenges.”

Companies are expected to spend $124 billion worldwide on information security products and services in 2019, and a large portion of that spending is to ensure GDPR compliance. And as cloud services become more and more popular, that market increases to an estimated $300 billion-plus by 2021. The adoption of cloud services is the way of the future, but it increases the need for sophisticated security. The newest version of ClassiDocs is certainly one of the most comprehensive solutions to the problem yet.


Republished by NextBigTicker.com

NextBigTicker.com has also recently featured Puration, Inc. (PURA), North American Cannabis Holdings, Inc. (USMJ) and Alternet Systems, Inc. (ALYI).

Full Article Source: https://medium.com/bigtoken/microsoft-ceo-says-data-privacy-is-a-human-right-the-week-in-data-privacy-and-transparency-27cddbaba0e1

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

GNBT - Goldman Small Cap Research Initiates Generex Coverage With $40 Target PPS Pre-Dividend

Goldman Small Cap Research - November 5, 2018

Every once in a while, we see an unusual situation and write about it to alert you to it. Today is one of those days. Normally idea would not be of a diversified health care stock that went from $2 to $25 (before settling back) in about a month. But, in this situation, there are interesting circumstances regarding a big stock dividend and an aggressive M&A strategy to match its R&D pipeline. News about an unusual dividend came out this morning and prompted this email. Against this backdrop, we issued a research report and an interview with the CEO this morning. Let me introduce it to you…

FAST FACTS

  • Almost overnight, Generex Biotechnology (OTC – GNBT) could go from also-ran to a firm generating revenue at an annual run-rate of hundreds of millions annually. The Company just closed on an acquisition that has generated $100M or more annually in recent years and is primed to grow dramatically as it begins to offer its services in 30 states, versus 3 this year.

  • There are more deals in the pipeline. Generex plans to become a diversified health care firm that utilizes cash from its high growth M&A targets to help fund its R&D in the areas where an unmet need exists. These include diabetes, breast cancer, prostate cancer and others.

  • The Company is collaborating with a Canopy Growth-invested firm to explore using one of its delivery system offerings for medical marijuana patients in Canada.

  • Generex announced a 20:1 stock dividend with a record date of Friday (which means investors must own the stock by Tuesday or Wednesday to be eligible to receive it). While there is likely to be a re-adjustment in share price as a result, the current market capitalization, compared with its likely revenue next year (via M&A) and underlying value of its portfolio, appears to be at a major discount.

The recent Generex Biotechnology (OTC – GNBT) Research Report is included below:

GNBT-11.5.18-[2]_Page_01.jpg
GNBT-11.5.18-[2]_Page_02.jpg
GNBT-11.5.18-[2]_Page_03.jpg
GNBT-11.5.18-[2]_Page_04.jpg
GNBT-11.5.18-[2]_Page_05.jpg
GNBT-11.5.18-[2]_Page_06.jpg
GNBT-11.5.18-[2]_Page_07.jpg
GNBT-11.5.18-[2]_Page_08.jpg
GNBT-11.5.18-[2]_Page_09.jpg
GNBT-11.5.18-[2]_Page_10.jpg

Source: http://www.goldmanresearch.com/201811051217/Opportunity-Research/new-interview-with-gnbt-ceo-and-a-new-research-report.html

OPTI – OPTEC International Inc Offers Proven Green Energy Solution In $700 Billion Market Segment

OPTI LOGO.jpg

New York, NY – November 5, 2018 – OPTEC International, Inc. (OTCQB) is, so far, a quiet little green energy firm producing an emissions reducing device built on a proven patented technology. The company is likely to become a recognized brand name in the near future.  OPTEC entered the market this past summer when it acquired rights to the emission reducing technology for the international market.  The OPTEC technology is packaged into a device that can be fitted onto a gasoline or diesel engine to improve fuel efficiency and reduce emissions.  Savings from reduced fuel consumption makes emissions reduction actually cost effective.  The OPTEC Fuel Maximizer works on personal transportation and is ideal for truck fleets.  The global automotive aftermarket sector size in 2016 was over $640 billion and is expected to reach over $722 billion by 2020. The technology is also applicable to generators producing electricity opening another entire market opportunity for OPTEC’s green energy solution. 

Green energy solutions that reduce harmful carbon emissions from existing petroleum powerplants is an underappreciated, but essential market segment.  The transition to electric powered transportation or other alternative fuel solutions is years away and in the meantime, carbon emissions reduction relies on improving the efficiency of existing petroleum fuel burning powerplants. OPTEC is a standout in this underappreciated market that will soon come to the market’s attention as endeavors like Tesla (NADAQ: TSLA) continue to run into roadblocks and setbacks.

$5.00 PPS Quick Double Potential

At $5.00 PPS with a 52-week high of $10.40 and only 3.2 million shares in the float, OPTEC presents an attractive opportunity for a quick double as the company’s practical green energy solution gains market awareness.

OPTEC Fuel Maximizer

The product is a small, non-intrusive system that connects to an engines fuse box and source of vacuum. It requires no tanks or water reservoirs. By definition the Optimized Fuel Maximizer is a hydrogen fuel cell and it’s function is to emit a micro amount of hydrogen and cooler air into the combustion chamber to complete the combustion of the fuel. The technology is fully patented by the manufacturer and has undergone rigorous third-party testing to support performance claims and engine safety.

Screen Shot 2018-11-05 at 6.57.37 AM.png

DISCLAIMER: NextBigTicker.com (NBT)is a third party publisher and news dissemination service provider. NBT is NOT affiliated in any manner with any company mentioned herein. NBT is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. NBT's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. NBT is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. NBT has not been compensated for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

Disclaimer/Safe Harbor:

This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.

Source: www.nextbigticker.com